

4th *International Conference*



Thrombosis and Hemostasis Issues in Cancer

Bergamo, Italy ■ October 26 - 28, 2007

Congress Center Giovanni XXIII

Program



www.bergamoconference.com

SPONSORS

Platinum



Gold



Bayer HealthCare
Bayer Schering Pharma



Silver



Bronze





4th International Conference on

Thrombosis and Hemostasis Issues in Cancer

Bergamo, Italy ■ October 26 - 28, 2007

Congress Center Giovanni XXIII

Program

Conference Chairmen

Anna **FALANGA**
Ospedali Riuniti di Bergamo
Department of Hematology/Oncology
SIMT - Hemostasis and Thrombosis Center
Largo Barozzi, 1
24128 Bergamo - ITALY
e-mail: annafalanga@yahoo.com

Benjamin **BRENNER**
Rambam Medical Center & Bruce
Rappaport Faculty of Medicine
Institute of Hematology
P.O. Box 9602
Haifa 31096, ISRAEL
e-mail: b_brenner@rambam.health.gov.il

Frederick R. **RICKLES**
The George Washington University
and Center for Science and Technology
Noblis, Inc
3150 Fairview Park Drive
Falls Church, VA 22042-4519, USA
e-mail: frederick.rickles@noblis.org

Organizing Committee

Tiziano BARBUI (*Honorary President of the Conference*)
Anna FALANGA
Benjamin BRENNER
Frederick R. RICKLES
Roberto LABIANCA
Marina MARCHETTI
Galit SARIG
Alfonso VIGNOLI
Donatella BALDUCCI
Laura RUSSO
Elena GATTI

Organizing Secretariat



Servizi C.E.C. Srl
Servizi Congressuali ed Eventi Culturali
Via Verdi, 18
24121 Bergamo - Italy
Phone +39.035.249899
Fax +39.035.237852
E-mail: info@bergamoconference.com



The meeting is held under the auspices of:

Scientific Societies and Associations



A.R.T.E.T.

Institutions



Program Overview

	FRIDAY 26 th	SATURDAY 27 th	SUNDAY 28 th	
8.00 ➡	Congress Secretariat Open: Registration	Registration	Registration	
8.30 ➡		Plenary Session II New Insights Into the Epidemiology of and Risk Factors for VTE <i>Room Oggioni</i>	Plenary Session VI Antithrombotics and Cancer (I) <i>Room Oggioni</i>	
8.45 ➡				
9.00 ➡				
9.15 ➡				
9.30 ➡				
9.45 ➡		Coffee Break		
10.00 ➡				
10.15 ➡				
10.30 ➡				
10.45 ➡	Coffee Break	Poster View		
11.00 ➡	Satellite Symposia <i>Rooms Alabastro & Oggioni</i>	Plenary Session III Platelets, Fibrinogen, von Willebrand Factor and Cancer Metastasis <i>Room Oggioni</i>	Plenary Session VII Antithrombotics and Cancer (II): Prophylaxis and Treatment of Venous Thromboembolism <i>Room Oggioni</i>	
11.15 ➡				
11.30 ➡				
11.45 ➡				
12.00 ➡				
12.15 ➡		Lunch		
12.30 ➡				
12.45 ➡				
13.00 ➡				
13.15 ➡		Delivery of Attendance Certificates		
13.30 ➡	Lunch Session <i>Room Alabastro</i>	Lunch Session <i>Room Alabastro</i>	Poster Discussion Sessions w/Snack Lunch Session I: Room Stucchi Session II: Room Alabastro “B” Session III: Room Novelli Session IV: Room Alabastro “A” Session V: Room Stucchi Session VI: Room Alabastro “B” Session VII: Room Novelli Session VIII: Room Alabastro “A”	
13.45 ➡				
14.00 ➡				
14.15 ➡				
14.30 ➡				
14.45 ➡		Plenary Session IV Oncogene-Mediated Clotting Activation, Signaling and Thrombotic Markers in Cancer- Associated Thrombosis <i>Room Oggioni</i>		
15.00 ➡				
15.15 ➡				
15.30 ➡				
15.45 ➡				
16.00 ➡	Opening remarks <i>Room Oggioni</i>	Coffee Break	Meeting Closed	
16.15 ➡				
16.30 ➡				
16.45 ➡				
17.00 ➡				
17.15 ➡		Plenary Session V Cancer-Associated Hemostatic Defects <i>Room Oggioni</i>		
17.30 ➡				
17.45 ➡				
18.00 ➡				
18.15 ➡				
18.30 ➡	Plenary Session I Tumor Angiogenesis, Cell Signaling and Blood Coagulation <i>Room Oggioni</i>			
18.45 ➡				
19.00 ➡				
19.15 ➡				
19.30 ➡				
19.45 ➡				
20.00 ➡				
20.15 ➡				
20.30 ➡				
20.45 ➡				
21.00 ➡				
21.15 ➡				
21.30 ➡				
21.45 ➡				
22.00 ➡				
22.15 ➡				
22.30 ➡				
22.45 ➡				
23.00 ➡				
23.15 ➡				
23.30 ➡				
23.45 ➡				
24.00 ➡				
24.15 ➡				
24.30 ➡				
24.45 ➡				
25.00 ➡				
25.15 ➡				
25.30 ➡				
25.45 ➡				
26.00 ➡				
26.15 ➡				
26.30 ➡				
26.45 ➡				
27.00 ➡				
27.15 ➡				
27.30 ➡				
27.45 ➡				
28.00 ➡				
28.15 ➡				
28.30 ➡				
28.45 ➡				
29.00 ➡				
29.15 ➡				
29.30 ➡				
29.45 ➡				
30.00 ➡				
30.15 ➡				
30.30 ➡				
30.45 ➡				
31.00 ➡				
31.15 ➡				
31.30 ➡				
31.45 ➡				
32.00 ➡				
32.15 ➡				
32.30 ➡				
32.45 ➡				
33.00 ➡				
33.15 ➡				
33.30 ➡				
33.45 ➡				
34.00 ➡				
34.15 ➡				
34.30 ➡				
34.45 ➡				
35.00 ➡				
35.15 ➡				
35.30 ➡				
35.45 ➡				
36.00 ➡				
36.15 ➡				
36.30 ➡				
36.45 ➡				
37.00 ➡				
37.15 ➡				
37.30 ➡				
37.45 ➡				
38.00 ➡				
38.15 ➡				
38.30 ➡				
38.45 ➡				
39.00 ➡				
39.15 ➡				
39.30 ➡				
39.45 ➡				
40.00 ➡				
40.15 ➡				

**SATELLITE
SYMPOSIA
& LUNCH SESSIONS**
Friday - October 26th, 2007



ORGANON Symposium (room Alabastro "A")

9.30am-10.30am
not CME accredited

**CANCER PATIENTS, THROMBOSIS AND HEPARIN-INDUCED
THROMBOCYTOPENIA (HIT)**

Chairman: P. Prandoni (Italy)

Introduction: Cancer, Thrombosis and HIT

P. Prandoni (Italy)

**Parallels between HIT and cancer hypercoagulability:
Implications for pathogenesis of venous limb ischemia**

T. Warkentin (Canada)

**Management strategies for patients
with anticoagulant-induced thrombosis**

A. Greinacher (Germany)

Friday - October 26th, 2007



GENTIUM Symposium (room Alabastro "B")

9.30am-11.00am
not CME accredited

**DEFIBROTIDE: UPDATE OF CLINICAL AND PRE-CLINICAL
STUDIES IN HEMATOLOGICAL MALIGNANCIES AND TRANSPLANT**

Chairmen: T. Barbui (Italy), D. Niederwieser (Germany)

Introduction

T. Barbui (Italy)

Role of Heparanase in Cancer

I. Vlodavsky (Israel)

**New insights on the Mechanisms of Action of Defibrotide:
Effects of Defibrotide on Heparanase expression**

C. Echart (Italy)

**Clinical Experience with Defibrotide in combination
treatment of Multiple Myeloma**

A. Palumbo (Italy)

Defibrotide for Treatment of Hepatic Veno-Occlusive Disease

P. Richardson (USA)

Defibrotide for Prevention of Hepatic Veno-Occlusive Disease

D. Niederwieser (Germany)

SATELLITE SYMPOSIA & LUNCH SESSIONS

Friday - October 26th, 2007



ICTHIC Symposium (room Oggioni)

11.00am-12.30pm

not CME accredited

STANDARDIZATION OF PROPHYLAXIS AND TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS

Chairmen: D. Prisco (Italy) / P. M. Sandset (Norway)

AIOM Guidelines (Italian Oncology Group)

R. Labianca (Italy)

NCCN Guidelines

M.B. Streiff (USA)

ASCO Guidelines

G. Lyman (USA) / A. Falanga (Italy)

Meta-analysis of antithrombotics effects on cancer survival

N. Kuderer (USA)

Friday - October 26th, 2007



SANOFI-AVENTIS Lunch Session (room Alabastro)

12.45pm-2.15pm

not CME accredited

VTE RISK MANAGEMENT

Chairmen: A. Falanga (Italy) / M.M. Samama (France)

VTE risk management in surgical oncological patients

G.C. Agnelli (Italy)

VTE treatment in oncological patients

D. Imberti (Italy)

The VTE long term prophylaxis in medical patients:

M. Carpenedo (Italy)

Discussion

Saturday - October 27th,



BAYER Lunch Session (room Alabastro)

1.00pm-2.00pm

not CME accredited

THE HAEMATOCRIT AND PLATELET TARGET IN POLYCYTHEMIA VERA

Chairman: T. Barbui (Italy)

Aspirin in chronic myeloproliferative disorders

R. Landolfi (Italy)

PROGRAM

4th International Conference on

Thrombosis and Hemostasis Issues in Cancer

Bergamo, Italy ■ October 26 - 28, 2007
Congress Center Giovanni XXIII

Friday - October 26th, 2007

SATELLITE SYMPOSIA

(See pages 7 and 8)

CONGRESS OPENING (room Oggioni)

2.30pm

Opening Remarks
Conference Chairmen

2.45pm

**Lecture: Blood Clotting, Fibrinolysis,
Platelets and Tumor Angiogenesis: An Overview**

P. Carmeliet (Belgium)

Chairmen: P.M. Mannucci (Italy), F.R. Rickles (USA)

SCIENTIFIC SESSIONS (room Oggioni)

4.00pm-6.00pm

PLENARY SESSION I

TUMOR ANGIOGENESIS, CELL SIGNALING AND BLOOD COAGULATION

Chairmen: F.R. Rickles (USA) / F. Rodeghiero (Italy)

Endothelial Cadherins and Tumor Angiogenesis

PL-01

E. Dejana, M.G. Lampugnani (Italy)

Tissue Factor and PAR signaling in Regulation of Tumor Angiogenesis

PL-02

W. Ruf (USA)

Role of Alternatively-Spliced Human Tissue Factor in Tumor Growth and Angiogenesis

PL-03

G.A. Soff (USA)

Tumor Cell-Associated Tissue Factor Supports Metastatic Potential Through both NK Cell-Dependent and -Independent Mechanisms

PL-04

J. S. Palumbo (USA)

Selected Abstracts

Inhibition of Anti-angiogenesis Cardiovascular Events and Chemotherapy Cardiotoxicity by Angioprevention Agents

OC-01

A. Albinì, D. Noonan, U. Pfeffer, G. Lorusso, N. Vannini (Italy)

Inflammatory-like Activation of Endothelial Cells in Hematogenous Metastasis

OC-02

H. Läubli & L. Borsig (Switzerland)

7.30pm

Welcome Party at the Art Gallery Accademia Carrara.

Followed by Guided tour of the Art Exhibition **"The Future of Futurism"**
at the GAMEC (Gallery of Modern and Contemporary Art)

PROGRAM

Saturday - October 27th, 2007

8.30am-10.30am

PLENARY SESSION II

NEW INSIGHTS INTO THE EPIDEMIOLOGY OF AND RISK FACTORS FOR VTE

Chairmen: M.H. Prins (The Netherlands) / M.B. Donati (Italy)

Which Tumors are most Thrombogenic and which should be Prioritized for Anticoagulant Trials?

PL-05

R.H. White (USA)

Approaches to Risk-stratifying Cancer Patients for VTE: A Predictive Model

PL-06

A.A. Khorana (USA)

Role of Thrombophilic Defects in Risk for VTE in Cancer

PL-07

H. Decousus (France)

Lessons Learned from Cancer/VTE Registries: Report from RIETE

PL-08

M. Monreal (Spain) & P. Prandoni (Italy)

Selected Abstract

A Population-based Cohort Study of the Incidence of Venous Thromboembolism in Danish Cancer Patients compared to the General Population

OC-03

D.P. Cronin-Fenton, F. Søndergaard, L. Pedersen, J.P. Fryzek, K. Cetin, J. Acquavella, H.T. Sørensen (USA, Denmark)

10.30am

Coffee Break

11.00am-1.00pm

PLENARY SESSION III

PLATELETS, FIBRINOGEN, von WILLEBRAND FACTOR AND CANCER METASTASIS

Chairmen: J.L. Degen (USA) / E. Tremoli (Italy)

Role of vWF in Tumor Metastasis

PL-09

C.V. Denis (France)

Thrombin-induced upregulation of Twist which induces angiogenesis

PL-10

S. Karparkin (USA)

Protease signaling in Tumor Progression

PL-11

E. Camerer (USA)

Selected Abstracts

The Role of Platelet Microparticles in Angiogenesis and Tumor Biology

OC-04

D. Varon, A. Brill, O. Dashevsky, T. Zelikovitz (Israel)

Protease-Activated Receptor-1 (PAR-1) Expression Correlates with Malignant Phenotype in Human Melanoma

OC-05

A. Silini, C. Ardinghi, F. Carraro, A. Naldini, M.R. Bani, R. Giavazzi (Italy)

1.00pm

Satellite Lunch Session (room Alabastro) (see page 8)

2.00pm-4.00pm

PLENARY SESSION IV
**ONCOGENE-MEDIATED CLOTTING ACTIVATION, SIGNALING AND
THROMBOTIC MARKERS IN CANCER-ASSOCIATED THROMBOSIS**

Chairmen: J-M. Freyssinet (France) / H.A. Liebman (USA)

**The Role of Tumor- and Host-Related Tissue Factor
in Oncogene-Driven Tumor Progression**
PL-12

J. Rak (Canada)

Use of TF-Deficient Mouse to Study Tumor Biology
PL-13

N. Mackman (USA)

TF-bearing Microparticles in Colorectal Cancer
PL-14

A. Weltermann (Austria)

Selected Abstracts
**Tissue Factor-Bearing Microparticles are associated with an increased
Risk of Venous Thromboembolic Events in Cancer Patients**
OC-06

J.I. Zwicker, C.A. Kos, K.A. Johnston, H.A. Liebman,
B.C. Furie, B. Furie (USA)

**Enhanced Thrombotic Activity in Association with Increased
Circulating Tissue Factor Activity in a Mouse Model**
OC-07

M.B. Taubman, C. Miller, R. Rossi, J. Harvey, E. Kuo, L. Wang, C. Ryan,
R. Swarthout, R.S. Komrokji, N. Uppal, C. Francis, A.A. Khorana (USA)

4.00pm

Coffee Break

4.30pm-6.30pm

PLENARY SESSION V
CANCER-ASSOCIATED HEMOSTATIC DEFECTS

Chairmen: M. Levi (The Netherlands) / T. Barbui (Italy)

JAK-2 mutations and Thrombosis in Myeloproliferative Disorders
PL-15

P.J. Campbell (UK)

Bleeding and Thrombosis in Bone Marrow Transplantation
PL-16

B. Brenner (Israel)

Bleeding and Thrombosis in Leukemia:
What does the Future of Therapy look like
PL-17

Panel Discussion: A. Falanga, F.R. Rickles, B. Brenner, M.A. Sanz,
P. Montesinos, T. Barbui

**How to Avoid the Problem of VTE in Women
receiving Adjuvant Therapy for Breast Cancer**
PL-18

M. Levine (Canada)

8.00pm

Opera Don Gregorio at the Donizetti Theatre

PROGRAM

Sunday - October 28th, 2007

8.30am-10.30am

PLENARY SESSION VI

ANTITHROMBOTICS AND CANCER (I)

Chairmen: L.R. Zacharski (USA) / A.K. Kakkar (UK)

Differential effects of Low-Molecular-Weight-Heparins on Selectin-Mediated Tumor Cell Adhesion and Metastasis

PL-19

L. Borsig (Switzerland)

Involvement of Heparanase in Cancer Metastasis, Angiogenesis and Inflammation

PL-20

I. Vlodavsky (Israel)

Modified heparan sulfates and glycol-split heparin as inhibitors of myeloma tumor growth

PL-21

R.D. Sanderson (USA)

The Effects of Dalteparin on VTE and Survival in Cancer

PL-22

A.Y.Y. Lee (Canada)

Selected Abstract

Effects of Low-Molecular-Weight Heparins on Metastatic Tumor Development in Animal Models

OC-08

C.J.F. Van Noorden, C.P.W. Klerk, T.M.H. Niers, L.W. Bruggemann, S.M. Smorenburg, T.L.M. Ten Hagen, C.A. Spek, O. Van Tellingen (The Netherlands)

10.30am

Coffee Break/Poster View (various rooms, see pages 13-20)

11.00am-1.00pm

PLENARY SESSION VII

ANTITHROMBOTICS AND CANCER (II): PROPHYLAXIS AND TREATMENT OF VENOUS THROMBOEMBOLISM

Chairmen: S. Schulman (Canada) / M.-M. Samama (France)

Prevention of VTE in Patients with Brain Tumors

PL-23

J. Perry (Canada), M. Levine (Canada)

Treatment of VTE with New Anticoagulants

PL-24

H.R. Büller (The Netherlands)

Thromboprophylaxis during Chemotherapy for Advanced Cancer

PL-25

G. Agnelli (Italy)

Prevention of VTE in Multiple Myeloma Patients

PL-26

M. Cavo, E. Zamagni (Italy)

Selected Abstracts

Usual Care Compared with Long-Term Low-Molecular-Weight Heparins in Patients with Cancer and Proximal Venous Thrombosis

OC-09

R.D. Hull (Canada)

Anticoagulant Effects after Termination of Therapy using Once Weekly Subcutaneous Injections of Idraparinux in Patients with Acute Venous Thromboembolism

OC-10

J. Harenberg, C.H. Weiss, I. Joerg, T. Fenyvesi, G. Mikus (Germany)

1.15pm-4.00pm

POSTER DISCUSSION SESSIONS I-VIII (various rooms, see pages 13-20) (with snack lunch near the Poster area)

7.00pm

Farewell Party at the Castle of Calepio

Poster Session I: Angiogenesis & Vascular Endothelium

Room "Stucchi"

Chairmen: A. Federici (Italy) - R. Giavazzi (Italy)

1.15 pm
2.30 pm

- PO-01 CISPLATIN INDUCES THROMBIN GENERATION VIA FORMATION OF PROCOAGULANT ENDOTHELIAL MICROPARTICLES IN VITRO**
D. Lechner, M. Kollars, A. Gleiss, P. A. Kyrle, A. Weltermann (Austria)
- PO-02 ENDOTHELIAL PROTEIN C RECEPTOR IN BREAST CANCER CELL LINES**
L. Tagliavacca, G. Fontana, C. Razzari, M. Cattaneo, E. M. Faioni (Italy)
- PO-03 bFGF, IL-6, TNF- α AND VEGF SERUM LEVELS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE, DEXAMETHASONE AND AUTOLOGOUS TRANSPLANTATION**
C. Cellini, V. Tazzari, T. Grafone, M. Conti, C. Baccini, E. Zamagni, D. Cangini, P. Tacchetti, P. Tosi, A. Zaccaria, M. Cavo (Italy)
- PO-04 HEPARANASE INDUCES TFPI EXPRESSION AND EXTRACELLULAR ACCUMULATION IN ENDOTHELIAL AND TUMOR CELLS.**
Y. Nadir, B. Brenner, S. Gingis-Velitski, F. Levy-Adam, N. Ilan, E. Zcharia, E. Nadir, I. Vlodavsky (Israel)
- PO-05 DETERMINANTS OF HOMOCYSTEINE LEVELS IN COLORECTAL AND BREAST CANCER PATIENTS**
P. Ferroni, R. Palmirotta, F. Martini, G. Ludovici, A. Magnapera, L. Rossi, M. Vergati, V. Formica, M. Roselli, F. Guadagni (Italy)
- PO-06 CHARACTERIZATION OF TFPI DEFICIENCY IN VASCULAR CELLS**
M. Sletten, T. Lien, N. Iversen (Norway)
- PO-07 DUAL IMPLICATION OF ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) IN CANCER HOMOEOSTASIS**
E. Ducros, S. Mirshahi, J. Y. Perrot, A. M. Faussat, L. Chauvenet, F. Daggonet, E. Pujade-Lauraine, J. Soria, M. Mirshahi (France)
- PO-08 DEFIBROTIDE, AN ANTI-THROMBOTIC DRUG, PREVENTS ANGIOGENESIS IN VITRO AND IN VIVO**
G. Eissner, G. E. Koehl, E. G. Geissler, E. Holler, and M. Iacobelli (Italy, Germany)
- PO-09 EXPRESSION OF ALTERNATIVELY SPLICED TISSUE FACTOR IN HUMAN ENDOTHELIAL CELLS: INDUCTION BY INFLAMMATORY STIMULI AND MODULATION BY HEPARINS**
M. Brambilla, D. Colnago, A. Pignieri, L. Mussoni, E. Tremoli, M. Camera (Italy)
- PO-10 IN VIVO EFFICACY OF HER1/EGFR TYROSINE KINASE INHIBITION IN ERLOTINIB RESISTANT PC3 PROSTATE CANCER CELLS IS ASSOCIATED TO REDUCED ENDOTHELIAL CELL ORGANIZATION AND INCREASED INFLAMMATORY INFILTRATION**
C. Festuccia, G. L. Gravina, P. Muzi, A. Vetuschi, R. Sferra, C. Vicentini and M. Bologna (Italy)
- PO-11 IMMUNITY, THROMBOSIS AND SURVIVAL IN LUNG ADENOCARCINOMA PATIENTS: A PROSPECTIVE STUDY**
E. de Meis, F. J. Rios, V. R. Pinheiro, M. M. Zamboni, M. T. S. Guedes, M. G. Premazzi, N. P. R. Silveira, M. A. L. Loures, R. O. Monteiro, R. A. Levy, M. A. Gidlund (Brazil)
- PO-12 THE PROTHROMBOTIC AND PROANGIOGENIC POTENTIAL OF MICROVASCULAR ENDOTHELIAL CELLS INDUCED BY TUMOR CELLS IS REDUCED BY THE LOW MOLECULAR WEIGHT HEPARIN (LMWH) DALTEPARIN**
A. Vignoli, M. Marchetti, L. Russo, D. Balducci, and A. Falanga (Italy)
- PO-13 LOW-MOLECULAR WEIGHT HEPARIN (LMWH) BEMIPARIN AND ULTRA-LOW-MW/H RO-14 INHIBIT LUNG, BREAST AND LEUKEMIA CANCER CELL-INDUCED ENDOTHELIAL ANGIOGENESIS**
A. Vignoli, M. Marchetti, E. Cantalino, L. Russo, D. Balducci, and A. Falanga (Italy)

Poster Session II: Thrombotic Markers

Room "Alabastro-B"

Chairmen: H. Ten Cate (The Netherlands) - S. Siragusa (Italy)

1.15pm
2.30pm

- PO-14 DIAGNOSTIC CHARACTERISTICS IN PATIENTS WITH CLINICALLY SUSPECTED DEEP VENOUS THROMBOSIS WITH AND WITHOUT MALIGNANCY**
G. L. van Sluis, P. W. Kamphuisen, H. R. Büller (The Netherlands)
- PO-15 SHOULD COMMON INHERITED THROMBOPHILIC ABNORMALITIES BE TESTED IN CANCER PATIENTS WITH CENTRAL VENOUS CATHETER?**
F. Dentali, M. Gianni, G. Agnelli, W. Ageno (Italy)
- PO-16 HEMOSTATIC ACTIVATION, FIBRINOLYSIS, AND ANGIOGENESIS PRIOR TO RADICAL RETROPUBIC PROSTATECTOMY**
S. T. Tagawa, T. B. Dorff, L. Rochanda, W. Ye, G. Lieskovsky, D. G. Skinner, D. I. Quinn, H. A. Liebman (USA)
- PO-17 PATTERNS OF PROCOAGULANT AND IMMUNOINFLAMMATORY RESPONSE FOLLOWING CHEMORADIOTHERAPY AND SURGERY FOR OESOPHAGEAL CANCER**
M. Byrne, J. O'Donnell, B. White, J. V. Reynolds (Ireland)
- PO-18 PULMONARY TUMOR EMBOLI: OFTEN REVIEWED AND CLINICALLY FORGOTTEN**
W. Patton, M. Salameh, A. Alpern (USA)
- PO-19 ARE QUANTITATIVE D-DIMER LEVELS ONLY USEFUL IN THE DIAGNOSIS OF VENOUS THROMBOSIS? PREDICTIVE ROLE OF QUANTITATIVE D-DIMER LEVELS IN PATIENTS WITH VENOUS THROMBOSIS**
S. Paneesha, K. French, E. Cheyne, P. Kesteven, H. Marr, A. Borg and P. Rose (UK)
- PO-20 ANTIPHOSPHOLIPID ANTIBODIES SPECTRUM IN GENITAL CANCER PATIENTS WITH THROMBOSIS IN PAST HISTORY**
A. Makatsaria, A. Vorobiev, V. Volkova (Russia)
- PO-21 CLINICAL SIGNIFICANCE OF REVEALING COMBINATION OF GENETIC FORMS OF THROMBOPHILIA AND APA IN CANCER PATIENTS WITH RECURRENT THROMBOSIS**
V. Volkova, A. Vorobiev, A. Makatsaria (Russia)
- PO-22 ASSESSMENT OF THROMBOTIC RISK IN CANCER PATIENTS: PROPOSAL FOR A SCORING SYSTEM. A MONOCENTRIC STUDY**
G. Giordano, G. Farina, R. Tambaro, M. Licursi, S. Piano, M. Specchia, S. Papini, P. Modugno, E. M. Centritto, B. Zappacosta, S. Storti (Italy)
- PO-23 CORRELATION OF THROMBOSIS AND PROTHROMBOTIC MARKERS WITH SURVIVAL IN LUNG ADENOCARCINOMA PATIENTS: A PROSPECTIVE STUDY**
E. de Meis, V. R. Pinheiro, M. M. Zamboni, M. T. S. Guedes, I. A. M. Castilho, A. J. U. B. Costa, M. S. O. Leda, I. C. Marques, R. Q. Monteiro, R. A. Levy (Brazil)
- PO-24 ELEVATED LEVELS OF FACTOR VIII IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH THALIDOMIDE**
B. Cosmi, C. Legnani, M. Cini, L. Valdrè, G. Palareti (Italy)
- PO-25 PREDICTIVE VALUE FOR VTE OF HEMOSTATIC MARKERS IN PATIENTS WITH MULTIPLE MYELOMA RECEIVING THALIDOMIDE**
A. Falanga, M. Galli, L. Russo, D. Balducci, A. Vignoli, M. Marchetti, A. Rambaldi and T. Barbui (Italy)
- PO-26 ACTIVATED FACTOR VII-ANTITHROMBIN COMPLEX (FVIIa-AT) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL)**
D. Balducci, L. Russo, A. Vignoli, M. Marchetti, B. Woodhams, J. Morrissey, T. Barbui, A. Falanga (Italy, France, USA)

Poster Session III: Platelets & Coagulation Proteases
Room "Novelli"

Chairmen: M. Cattaneo (Italy) - R. Lorenzet (Italy)

 **1.15pm
2.30pm**

- PO-27 RAISED LEVELS OF CD39 IN LEUCOCYTOSIS RESULT IN MARKED INHIBITION OF ADP-INDUCED PLATELET AGGREGATION VIA RAPID ADP HYDROLYSIS**
S. Heptinstall, B. Myers, S. C. Fox, J. R. Glenn, A. J. Johnson, A. E. White (UK)
- PO-28 EXPRESSION OF TISSUE FACTOR (TF), TISSUE FACTOR PATHWAY INHIBITOR (TFPI), FACTOR IX AND FACTOR X IN BREAST CANCER: COMPARISON BETWEEN PRIMARY TUMOR AND METASTATIC LESIONS IN REGIONAL LYMPH NODES**
M. Z. Wojtukiewicz, E. Sierko, Z. Sawicki, L. Zimnoch, W. Kisiel (Poland, USA)
- PO-29 CANCER PROCOAGULANT EXPRESSION AND FIBRIN CLOT FORMATION IN THE TUMOR CELLS ENVIRONMENT IN VITRO**
K. Kaplinska, U. Krajewska, M. Rozalski and W.P. Mielicki (Poland)
- PO-30 EXPRESSION ANALYSIS OF A MISSENSE MUTATION IN THE PROTEIN C GENE IN CANCER CELL LINES**
L. Tjeldhorn, N. Iversen, K. Haugbro, P. M. Sandset, G. Skretting (Norway)
- PO-31 THROMBIN CLEAVES IN VITRO FGF-2 AND MODULATES ITS BIOLOGICAL ACTIVITY**
P. Totta, R. De Cristofaro, M. C. Capogrossi and A. Facchiano (Italy)
- PO-32 PLASMINOGEN ACTIVATOR INHIBITOR-1 4G/5G POLYMORPHISM IN BREAST CANCER**
R. Palmirotta, P. Ferroni, A. Savonarola, F. Martini, F. Ciatti, A. Laudisi, E. Fossile, G. Del Monte, F. Guadagni, M. Roselli (Italy)
- PO-33 ELEVATED LEVELS OF PLATELET AND ENDOTHELIAL MICROPARTICLES IN PATIENTS WITH ESSENTIAL THROMBOCYTHAEMIA**
M. Trappenburg, M. van Schilfgaarde, M. Marchetti, D. Balducci, A. Leyte, W. E. Terpstra, A. Falanga (The Netherlands, Italy)
- PO-34 EFFECT OF THROMBIN AND PLATELETS ON OVARIAN CANCER CELL INVASION**
D. L. Ornstein, C. E. Holmes (USA)
- PO-35 ROLE OF PLATELET AND TUMOUR CELL RECEPTORS IN BREAST ADENOCARCINOMA MDA-MB-231 CELL ADHESION TO THE SUBENDOTHELIUM IN WHOLE BLOOD AND UNDER FLOW CONDITIONS**
I. Djaafri, N. Gomes, F. Quinto, A. Bruel, C. Legrand, F. Fauvel-Lafève (France)
- PO-36 A HIGH PLATELET COUNT INDEPENDENTLY PREDICTS VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: RESULTS FROM THE VIENNA CANCER AND THROMBOSIS STUDY (CATS)**
R. Simanek, R. Vormittag, G. Alguet, C. Ay, D. Dunkler, P. Quehenberger, C. Zielinski, U. Jaeger, I. Pabinger (Austria)
- PO-37 HYPOXIA INDUCES THE EXPRESSION OF PROTEASE-ACTIVATED RECEPTOR (PAR)-1 THROUGH THE HYPOXIC INDUCIBLE FACTOR (HIF)-1a IN MDA-MB-231 BREAST CANCER CELLS**
I. Filippi, C. Ardinghi, R. Giavazzi, F. Carraro, A. Naldini (Italy)
- PO-38 INCREASED EXPRESSION OF TISSUE FACTOR, PAR-1 AND INTERLEUKIN-8 IN ESOPHAGEAL CANCER PATIENTS**
F. Ribeiro, T. Simão, N. Amoedo, F. Rumjaneck, L. Ribeiro-Pinto, R. Albano, R. Monteiro (Brazil)

Poster Session IV: Prophylaxis and Treatment of Thrombosis and Bleeding Room "Alabastro-A"

Chairmen: B. Cosmi (Italy) - G. Finazzi (Italy)

1.15pm
2.30pm

- PO-39 THE MANAGEMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH ADVANCED METASTATIC CANCER: EXPERIENCES OF A PALLIATIVE CARE SERVICE**
S. I. R. Noble, K. Hood, I. G. Finlay (Wales, The Netherlands)
- PO-40 PRODIGE: A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF LONG-TERM THROMBOPROPHYLAXIS USING DALTEPARIN LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT GLIOMA: UPDATED RESULTS**
J. Perry, L. Rogers, N. Laperriere, J. Julian, W. Geerts, G. Agnelli, M. Malkin, R. Sawaya, (Canada)
- PO-41 MULTIDETECTOR CT OF DEEP VENOUS THROMBOSIS IN A GYNECOLOGICAL ONCOLOGIC PATIENT: A CASE REPORT**
M. Renni, C. Queiroz, R. Muniz, M. Cardozo, C. Camisã (Brazil)
- PO-42 LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) IN ACUTE LEUKAEMIA (AL) PATIENTS WITH SEVERE THROMBOCYTOPENIA AND CONCOMITANT VENOUS OR ARTERIAL THROMBOSIS.**
M. Cedrone, A. Chierichini, P. Anticoli Borza, S. Fenu, V. Bongarzone, B. Anaclerio, M. Bartolini, B. Ronci, A. Venditti, D. Venditti, M. Quaresima, L. Maurillo, P. De Fabritiis and L. Annino (Italy)
- PO-43 LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN CENTRAL VENOUS CATHETER ANTITHROMBOTIC PROPHYLAXIS: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS**
D. Tassinari, E. Scarpi, S. Rupoli (Italy)
- PO-44 INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING THORACOTOMY FOR CANCER**
F. Dentali, A. Malato, W. Ageno, S. Siragusa, J. Douketis, M. Crowther (Italy, Canada)
- PO-45 DO ALL PATIENTS WITH VENOUS THROMBOSIS REQUIRE SCREENING FOR MALIGNANCY? A PREDICTIVE MODEL TO IDENTIFY PATIENTS WITH VTE AT MINIMAL RISK OF MALIGNANCY**
S. Paneesha, W. Zhang, N. Parsons, P. Kesteven, H. Marr, A. Borg and P. Rose (UK)
- PO-46 VENOUS THROMBOSIS (VTE) SHORTENS THE SURVIVAL IN PATIENTS WITH MALIGNANCY**
S. Paneesha, A. Lokare, Z. Lester, T. Nokes, R. Arya, T. Farren, A. McManus, F. Pressley, N. Scriven, D. O'Shaughnessy and P. Rose (UK)
- PO-47 LOW MOLECULAR WEIGHT HEPARIN (LMWH) ADMINISTRATION IN PATIENTS SUFFERING FROM PULMONARY EMBOLISM AND BRAIN METASTASES (mts): A REPORT OF TWO CASES**
F. V. Vitale, S. Rotondo, M. La Greca, A. Parisi, V. Giamo, F. Ferraù (Italy)
- PO-48 ASYMPTOMATIC INFERIOR VENA CAVA AND ILIAC VEIN THROMBOSIS IN CANCER PATIENTS: A DIFFICULT DIAGNOSIS AND TREATMENT MANAGEMENT**
F. J. Casals, C. Font, M. T. De Caralt, G. Escolar, P. Gascon (Spain)
- PO-49 PREVENTING SURGICAL BLOOD LOSS IN CANCER PATIENTS USING FIBRIN MONOMER AND F. XIII - PROOF OF CONCEPT WITH A DOUBLE BLIND RANDOMIZED TRIAL**
W. Korte, K. Gabi, A. Gähler, E. Kownacki, J. Lange, T. Schnider (Switzerland)
- PO-50 MANAGEMENT PRACTICES OF CONNECTICUT PHYSICIANS FOR TREATMENT OF CANCER PATIENTS WITH VENOUS THROMBOSIS**
R. Dhami, A. Bulgaru, K. Jagathambal, S. C. Johnson, D. Kapur, D. E. Slater, M. S. Dhami (USA)
- PO-51 THROMBOSIS AND CENTRAL VENOUS CATHETERS IN CANCER PATIENTS**
A. M. Young, S. Anderson, A. Ashton, G. Begum, D. Hunter, S. Wronski (UK)

Poster Session V: Anticancer Effects of Antithrombotics
Room "Stucchi"

Chairmen: W. Ageno (Italy) - A. Piccioli (Italy)

2.45pm
4.00pm

- PO-52 HEPARINS INHIBIT LUNG CANCER CELLS PROLIFERATION IN VITRO**
Y. Carmazzi, T. Neri, M. Iorio, R. Vanacore, A. Celi (Italy)
- PO-53 PHASE II STUDY OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN COMBINATION WITH IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA PATIENTS.**
I. Tsimafeyeu, A. Madzhuga, L. Demidov, O. Somonova, A. Yelizarova (Russian Federation)
- PO-54 HIGH DOSE WARFARIN INHIBITS CELL PROLIFERATION AND INDUCES APOPTOSIS IN LEUKAEMIA K562 AND HL-60 CELLS**
T. Ulutin, I. Onaran, S. Sencan, H. Demirtas, B. Aydemir (Turkey)
- PO-55 THE PERSISTENCE OF RESIDUAL VEIN THROMBOSIS, AFTER AN EPISODE OF DEEP VEIN THROMBOSIS, AND THE RISK OF NEW OVERT CANCER**
S. Siragusa, A. Malato, V. Cigna, F. Fulfarò*, R. Anastasio, G. Saccullo, I. Abbene, L. Lo Coco, A. Casuccio (Italy)
- PO-56 CHEMOANTICOAGULATION VERSUS CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): RESULTS OF THE INTERIM ANALYSIS OF THE FRAGEM TRIAL**
A. Maraveyas, M. Holmes, F. Lofts, K. K. Garadi, E. Gardiner, K. Wedgewood, J. Sgouros (UK)
- PO-57 ANTINEOPLASTIC ROLE OF ENOXAPARIN IN NEUROECTODERMAL TUMOR CELL LINES**
N. Crescenzo, N. Bertorello, A. Doria, L. Foglia, P. Angelini, R. Manicone, P. Saracco, F. Timeus (Italy)
- PO-58 LOW-MOLECULAR WEIGHT HEPARIN ANTAGONIZES THE CXCL12-DRIVEN MIGRATION OF CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS**
F. Vianello, M. C. Poznansky, A. Furlan, A. Piccioli, P. Prandoni (Italy, USA)
- PO-59 LOW MOLECULAR WEIGHT HEPARIN (LMWH) VERSUS BEST SUPPORTIVE CARE IN CANCER PATIENTS. A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS**
S. Laporte, G. Meyer, H. Buller, H. Decousus, N. Moulin, M. Cucherat, P. Mismetti (France)
- PO-60 META-ANALYSIS OF RANDOMISED COMPARISONS BETWEEN THE EFFECTS OF WARFARIN AND LOW MOLECULAR WEIGHT HEPARIN IN THROMBOPROPHYLAXIS AND MORTALITY IN CANCER PATIENTS**
A. M. Young, L. Gross, R. Hills and K. Wheatley (England)
- PO-61 CANCER AND SYMPTOMATIC VENOUS THROMBOEMBOLISM RATES: VERITY REGISTRY FINDINGS**
P. Rose, P. Shankara, A. McManus, Z. Lester, T. Nokes, T. Farren, N. Scriven, R. Arya, D. O'Shaughnessy for the VERITY Investigators (UK)
- PO-62 PROCOAGULANT PROPERTIES OF U87MG HUMAN GLIOBLASTOMA CELLS AND MOLECULAR TARGETS OF THE ANTICOAGULANT AND ANTITUMOR AGENT IXOLARIS**
T. C. Carneiro-Lobo, S. Konig, M. C. Sogayar, I. M. B. Francischetti, R. Q. Monteiro (Brazil, USA)
- PO-63 COMBINING CHEMOTHERAPY AND LOW-MOLECULAR-WEIGHT HEPARIN FOR THE TREATMENT OF ADVANCED BREAST CANCER: RESULTS ON CLINICAL RESPONSE, TRANSFORMING GROWTH FACTOR-BETA 1 AND FIBRIN MONOMER IN A PHASE II STUDY**
N. Seeholzer, B. Thürlimann, D. Köberle, D. Hess, W. Korte (Switzerland)

Poster Session VI: Hypercoagulability

Room "Alabastro-B"

Chairmen: P. Simioni (Italy) - S. Testa (Italy)

2.45pm
4.00pm

PO-64 INDUCTION OF TISSUE FACTOR AND LOSS OF THROMBOMODULIN ACTIVITIES UPON INFLAMMATORY STIMULATION IN VIVO

H. M. H. Spronk, K. Frederix, I. M. Kooter, R. van Oerle, D. Fens, K. Hamulyak, M. E. Gerlofs-Nijland, H. ten Cate (The Netherlands)

PO-65 IS ABNORMAL COAGULATION A POSSIBLE PROGNOSTIC FACTOR FOR EFFICACY OF IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA PATIENTS?

A. Madzhuga, I. Tsimafeyeu, L. Demidov, O. Somonova, A. Yelizarova (Russian Federation)

PO-66 ABNORMAL FIBRIN FORMATION SECONDARY TO MULTIPLE MYELOMA

J. E. Dyr, R. Kotlín, T. Riedel, P. Salaj, J. Suttnar, P. Klener (Czech Republic)

PO-67 HYPERCOAGULABLE PARAMETERS AS PREDICTORS OF PROGNOSIS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CARCINOMA

G. Sarig, A. Meir, M. Wollner, B. Brenner, N. Haim (Israel)

PO-68 TEG: A POTENTIAL MARKER OF THROMBOEMBOLIC RISK IN CANCER PATIENTS?

L. Bochsén, G. Dagaard, P. I. Johansson (Denmark)

PO-69 ACTIVATED PROTEIN C (APC) RESISTANCE IN HEMATOLOGICAL MALIGNANCIES

H. F. S. Negaard, P. O. Iversen, B. Ostenstad, M. C. Mowinkel, P. M. Sandset (Norway)

PO-70 PREVALENCE OF HEREDITARY AND ACQUIRED THROMBOPHILIA IN PATIENTS WITH GYNAECOLOGIC MALIGNANCY AND WOMEN WITH BREAST CANCER

S. Dilenge, E. Velten, G. Hommel, A. Teichmann, G-F. v. Tempelhoff (Germany)

PO-71 DETECTION OF PROCOAGULANT PHOSPHOLIPIDS IN PLASMA FROM PATIENTS WITH THYROID CANCER

B. Woodhams, A. Rousseau, S. Fontaine, P. Van Dreden (France)

PO-72 A RARE CASE OF PORTAL VEIN THROMBOSIS COMPLICATING JUVENILE IDIOPATHIC MYELOFIBROSIS WITH INTRAHEPATIC HAEMATOPOIESIS

S. Pulini, R. Di Lorenzo, A. M. Morelli, E. D'Amico, M. Mereu, R. Basilico, G. Fioritoni (Italy)

PO-73 PREVALENCE OF CANCER AND CONGENITAL THROMBOPHILIA IN 435 PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM (VTE)

A. Achkar, M. H. Horellou, X. Leclercq, Y. Lambert, J. Conard, J. P. Laaban, M. M. Samama (France)

PO-74 HYPERCOAGULABILITY IN MULTIPLE MYELOMA

A. D. Petropoulou, G. T. Gerotziakas, E. Verdy, F. Rendu, M. M. Samama, M. Hatmi, I. Elalamy (France)

PO-75 THROMBIN GENERATION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET)

M. Marchetti, E. Castoldi, H. M. H. Spronk, D. Balducci, T. Barbui, J. Rosing, H. ten Cate, A. Falanga (The Netherlands, Italy)

Poster Session VII: Tumor Tissue Hemostatic Properties
Room "Novelli"

Chairmen: S. Gordon (USA) - M. Camera (Italy)

**2.45pm
4.00pm**

- PO-76 ALTERATIONS IN OESTRADIOL-MEDIATED OESTROGEN RECEPTOR ALPHA ACTIVITY IN BREAST CANCER CELLS IN RESPONSE TO EXOGENOUS TISSUE FACTOR**
M. E. W. Collier, C. Li, C. Ettelaie (UK)
- PO-77 THE INFLUENCE OF TISSUE FACTOR ON THE METHYLATION OF OESTROGEN RECEPTOR ALPHA GENE DURING BREAST CANCER**
M. E. W. Collier, C. Li, C. Ettelaie (UK)
- PO-78 A UNUSUAL CASE OF PULMONARY THROMBOEMBOLISM**
L. Giusto, A. Vanini, G. B. Vigna, C. Gilli (Italy)
- PO-79 REDUCTION OF SERUM TISSUE FACTOR LEVELS (BB-TF) IN ADVANCED PANCREATIC CANCER (APC) PATIENTS TREATED WITH DALTEPARIN CORRELATES WITH REDUCTION OF CHEMOTACTIC PROPERTIES OF PATIENTS' SERA: RESULTS FROM THE FRAGEM TRANSLATIONAL STUDY**
A. Maraveyas, C. Li, J. Greenman, C. Ettelaie (UK)
- PO-80 FUNCTIONAL ENDOTHELIAL PROTEIN C RECEPTOR DETECTED ON HUMAN MALIGNANT CELLS**
E. Ducros, S. Darvishi, S. S. Mirshahi, A. M. Faussat, A. Rafii Tabrizi, J. Soria, M. Mirshahi (France)
- PO-81 ASSOCIATION BETWEEN TUMOUR TISSUE FACTOR EXPRESSION AND CODON 12 K-ras MUTATION IN NON-SMALL CELL LUNG CANCER**
S. Regina, J. Rollin, C. Bléchet, J. B. Valentin, P. Reverdiau, Y. Gruel (France)
- PO-82 ENDOGENOUS PRODUCTION OF NITRIC OXIDE CONTROLS THE ACTIVATION STATE OF CELL SURFACE TISSUE FACTOR**
H. Liang, T. M. Brophy, P. Bhattacharyya, P. J. Hogg (Australia)
- PO-83 DIFFERENTIAL PROCOAGULANT PHENOTYPE OF PANCREATIC AND BREAST CANCER CELLS RELATED TO DIFFERENT TISSUE FACTOR ACTIVITY**
G.T. Gerotziafas, I. Elalamy, M. P. Roman, C. Prengel, E. Verdy, J. F. Bernaudin (France)
- PO-84 LEPTIN ENHANCES TISSUE FACTOR EXPRESSION BY THE HUMAN BREAST CANCER CELL LINE MCF7**
E. Napoleone, F. Zurlo, M. C. Latella, L. Iacoviello, M. B. Donati, R. Lorenzet (Italy)
- PO-85 MALIGNANT TRANSFORMATION IN MELANOCYTES INCREASES THE PRODUCTION OF PROCOAGULANT MICROVESICLES**
L. G. Lima, M. A. Barcinski, R. O. Monteiro (Brazil)
- PO-86 INTEGRIN ALPHA(V)BETA(3) AND OSTEOPONTIN PROMOTE HEMATOGENOUS METASTASIS OF OSTEOSARCOMA CELLS TO THE LUNG**
W. A. Hassenpflug, M. P. Tschan, B. E. Torbett, B. Felding-Habermann (USA, Germany, Switzerland)
- PO-87 TISSUE FACTOR INHIBITION IN HUMAN CANCER AND TUMOR-ASSOCIATED HOST CELLS BY PACLITAXEL**
E. Napoleone, F. Zurlo, C. Amore, A. Di Santo, M. C. Latella, L. Iacoviello, M. B. Donati, R. Lorenzet (Italy)
- PO-88 LOCALIZATION OF COAGULATION PROTEINS IN MALIGNANT COLON TISSUE**
J. M. M. B. Otten, H. M. H. Spronk, I. C. M. Mos, J. Govers-Riemslog, J. Westerga, M. Marchetti, A. Falanga, H. ten Cate for the Amsterdam-Bergamo-Maastricht study group on Cancer and Thrombosis (The Netherlands, Italy)

Poster Session VIII: Epidemiology of Vascular Complications in Cancer

Room "Alabastro-A"

Chairmen: A. Inbal (Israel) - D. Imberti (Italy)

2.45 pm

4.00 pm

- PO-89 EVALUATION OF SOME HEMOSTATIC PARAMETERS IN PATIENTS WITH END-STAGE RENAL DISEASE: RELATION TO DYSLIPIDEMIA AND HEMODIALYSIS THERAPY**
N. Sayed-Ahmed, A. Hegazy, N. Abou-Samra, T. Selim, H. Azzam, S. ELshaarawy (Egypt)
- PO-90 CLINICAL CHARACTERISTICS OF CANCER ASSOCIATED ACUTE VENOUS THROMBOEMBOLISM: FINDINGS FROM THE MASTER REGISTRY**
D. Imberti, G. Agnelli, W. Ageno, M. Moia, G. Palareti, R. Pistelli, R. Rossi, M. Verso, for the MASTER investigators (Italy)
- PO-91 VENOUS THROMBOSES IN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKAEMIA (FRALLE 2000)**
B. Pautard, J. Micheli, A. Auvrignon, M.F. Auclerc, V. Li Thiao Te, P. Bordigoni, H. Chambost, F. Mechinaud, J.L. Dalle, M.D. Tabone, J.P. Vannier, Y. Perel, F. Demeocq, G. Leverger, A. Baruchel for FRALLE Group (France)
- PO-92 HIGH PREOPERATIVE PREVALENCE OF DEEP VENOUS THROMBOSIS IN PATIENTS WITH COLORECTAL CANCER**
M. T. Stender, T. S. H. Nielsen, J. B. Frøkjær, T. B. Larsen, S. Lundbye-Christensen, H. Elbrønd, O. Thorlacius-Ussing (Denmark)
- PO-93 COMBINED USE OF CLINICAL PRETEST PROBABILITY AND D-DIMER TEST IN THE DIAGNOSIS OF PREOPERATIVE DEEP VENOUS THROMBOSIS IN COLORECTAL CANCER PATIENTS**
M. T. Stender, J. B. Frøkjær, T. S. H. Nielsen, T. B. Larsen, S. Lundbye-Christensen, H. Elbrønd, O. Thorlacius-Ussing (Denmark)
- PO-94 HIGHER RISK OF DEATH IN PATIENTS WITH CERVICAL CANCER IIIB WITH VENOUS THROMBOEMBOLISM IN RIO DE JANEIRO, BRAZIL**
M. Renni, F. Russomano, M. Cardozo, L. Mathias, C. Camisão (Brazil)
- PO-95 VENOUS THROMBOEMBOLISM (VTE) IS ASSOCIATED WITH RECURRENT CANCER IN PATIENTS WITH INITIALLY NON-METASTATIC BREAST, LUNG, AND COLON CANCER**
T. Wun, H. Chew, H. Zhou, D. Harvey, R. White
- PO-96 THE INCIDENCE OF CANCER AFTER AN IDIOPATHIC THROMBOPHLEBITIS - A HISTORIC FOLLOW-UP STUDY IN PRIMARY CARE**
F. F. v. Doormaal, S. Atalay, E. F. v. d. Velde, H. Brouwer, H. Buller, H. van Weert (The Netherlands)
- PO-97 CENTRAL VENOUS LINES RELATED VENOUS THROMBOSIS (CVL-VT) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): OUTCOME AND IMPACT ON SURVIVAL**
P. Saracco, N. Bertorello, L. Garbarini, G. Pastore, E. Barisone, L. Artesani, L. Farinasso, L. Cordero di Montezemolo (Italy)
- PO-98 VENOUS THROMBOEMBOLISM (VTE) AS FIRST SIGN OF OCCULT MALIGNANCY IS ASSOCIATED WITH INCREASED RISK OF RECURRENT VTE**
S. Brækkan, E. M. Johansen, E. B. Mathiesen, I. Njølstad, T. Wilsaard, J. Størmer, J.-B. Hansen (Norway)
- PO-99 OUTCOMES IN CANCER PATIENTS WITH UNSUSPECTED PULMONARY EMBOLI FOUND ON STAGING CT SCANS**
C. O'Connell, L. Mark, W. Boswell, S. Boyle, S. Vasan, M. Ghalichi, H. A. Liebman (USA)
- PO-100 FACTOR V LEIDEN (FVL), PROTHROMBIN, MTHFR AND PAI-1 POLYMORPHISMS AND CANCER RISK IN WOMEN; THE JERUSALEM PERINATAL STUDY (JPS)**
E. Tiram, Y. Friedlander, L. Kadouri, O. Manor, R. Isacson, R. Yanetz, L. Deutsch, S. Harlap, O. Paltiel (Israel, USA)
- PO-101 INCIDENCE, CLINICAL-LABORATORY FEATURES, MANAGEMENT AND FOLLOW-UP OF ACQUIRED VON WILLEBRAND SYNDROME AND OTHER ACQUIRED DEFECTS OF HEMOSTASIS IN A COHORT OF 135 PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS**
M. T. Pugliano, M. T. Canciani, R. Garavaglia, R. Bader, P. Bucciarelli and A. B. Federici (Italy)
- PO-102 INCIDENTAL, ASYMPTOMATIC, UNSUSPECTED PULMONARY EMBOLISM IN CANCER PATIENTS: CASE-REPORTS**
M. Silingardi, D. Arioli, A. Pizzini, I. Iori (Italy)
- PO-103 EPIDEMIOLOGICAL STUDY: CAUSES OF DEATHS IN PTOLEMAIDA CITY**
M. P. Makris, L.P. Makri, S. I. Papamichos, P. E. Makris (Greece)
- PO-104 NON HODGKIN LYMPHOMA (NHL) AND DEEP VENOUS THROMBOSIS: A DANGEROUS LIAISON STILL UNEXPLORED**
G. Giordano, S. Piano, R. Marra, L. Iacoviello, V. De Stefano, G. Leone, S. Hohaus, M.B. Donati, S. Storti (Italy)

A

Abbene, I.PO -55
Abou-Samra, N.PO -89
Achkar, A.PO -73
Acquavella, J.O C-03
Ageno, W.PO -15, PO -44, PO -90
Agnelli, G.PL-25, PO -15,
PO -40, PO -90
Albano, R.PO -38
Albini, A.O C-01
Alguel, G.PO -36
Alpern, A.PO -18
Amoedo, N.PO -38
Amore, C.PO -87
Anaclerico, B.PO -42
Anastasio, R.PO -55
Anderson, S.PO -51
Angelini, P.PO -57
Annino, L.PO -42
Anticoli Borza, P.PO -42
Ardinghi, C.O C-05, PO -37
Arioli, D.PO -102
Artesani, L.PO -97
Arya, R.PO -46, PO -61
Ashton, A.PO -51
Atalay, S.PO -96
Auclerc, M.F.PO -91
Auvrignon, A.PO -91
Ay, C.PO -36
Aydemir, B.PO -54
Azzam, H.PO -89

B

Baccini, C.PO -03
Bader, R.PO -101
Baker, R.PO -40
Balducci, D.PO -12, PO -13, PO -25,
PO -26, PO -33, PO -75
Bani, M.R.O C-05
Barbui, T.PL-17, PO -25,
PO -26, PO -75
Barcinski, M.A.PO -85
Barisone, E.PO -97
Bartolini, M.PO -42
Baruchel, A.PO -91

Basilico, R.PO -72
Begum, G.PO -51
Bernaudin, J.F.PO -83
Bertorello, N.PO -57, PO -97
Bhattacharyya, P.PO -82
Bléchet, C.PO -81
Bochsen, L.PO -68
Bologna, M.PO -10
Bongarzone, V.PO -42
Bordigoni, P.PO -91
Borg, A.PO -19, PO -45
Borsig, L.PL-19, O C-02
Boswell, W.PO -99
Boyle, S.PO -99
Brambilla, M.PO -09
Brenner, B.PL-16, PL-17,
PO -04, PO -67
Brill, A.O C-04
Brækkan, S.PO -98
Brophy, T.M.PO -82
Brouwer, H.PO -96
Bruel, A.PO -35
Bruggemann, L.W.O C-08
Bucciarelli, P.PO -101
Bulgaru, A.PO -50
Büller, H.R.PL-24, PO -14,
PO -59, PO -96
Byrne, M.PO -17

C

Camera, M.PO -09
Camerer, E.PL-11
Campbell, P.J.PL-15
Camisã, C.PO -41, PO -94
Canciani, M.T.PO -101
Cangini, D.PO -03
Cantalino, E.PO -13
Capogrossi, M.C.PO -31
Cardozo, M.PO -41, PO -94
Carmazzi, Y.PO -52
Carneiro-Lobo, T.C.PO -62
Carraro, F.O C-05, PO -37
Casals, F.J.PO -48
Castilho, I.A.M.PO -23
Castoldi, E.PO -75

Casuccio, A.PO -55
Cattaneo, M.PO -02
Cavo, M.PL-26, PO -03
Cedrone, M.PO -42
Celi, A.PO -52
Cellini, C.PO -03
Centritto, E.M.PO -22
Cetin, K.O C-03
Chambost, H.PO -91
Chauvenet, L.PO -07
Chew, H.PO -95
Cheyne, E.PO -19
Chierichini, A.PO -42
Ciatti, F.PO -32
Cigna, V.PO -55
Cini, M.PO -24
Collier, M.E.W.PO -76, PO -77
Colnago, D.PO -09
Conard, J.PO -73
Conti, M.PO -03
Cordero di Montezemolo, L.PO -97
Cosmi, B.PO -24
Costa, A.J.U.B.PO -23
Crescenzo, N.PO -57
Cronin-Fenton, D.P.O C-03
Crowther, M.PO -44
Cucherat, M.PO -59

D

Daggonet, F.PO -07
Dalle, J.L.PO -91
D'Amico, E.PO -72
Darvishi, S.PO -80
Dashevsky, O.O C-04
Daugaard, G.PO -68
De Caralt, M.T.PO -48
De Cristofaro, R.PO -31
De Fabritiis, P.PO -42
de Meis, E.PO -11, PO -23
De Stefano, V.PO -104
Decousus, H.PL-07, PO -59
Dejana, E.PL-01
Del Monte, G.PO -32
Demeocq, F.PO -91
Demidov, L.PO -53, PO -65

AUTHOR INDEX

[illegible]

Iorio, M.	PO -52
Isacson, R.	PO -100
Iversen, N.	PO -06, PO -30
Iversen, P.O.	PO -69

J

Jaeger, U.	PO -36
Jagathambal, K.	PO -50
Joerg, I.	OC-10
Johansen, E.M.	PO -98
Johansson, P.I.	PO -68
Johnson, A.J.	PO -27
Johnson, S.C.	PO -50
Johnston, K.A.	OC-06
Julian, J.	PO -40

K

Kadouri, L.	PO -100
Kamphuisen, P.W.	PO -14
Kaplinska, K.	PO -29
Kapur, D.	PO -50
Karparkin, S.	PL-10
Kesteven, P.	PO -19, PO -45
Khorana, A.A.	PL-07, OC-07
Kisiel, W.	PO -28
Klener, P.	PO -66
Klerk, C.P.W.	OC-08
Köberle, D.	PO -63
Koehl, G.E.	PO -08
Kollars, M.	PO -01
Komrokji, R.S.	OC-07
Konig, S.	PO -62
Kooter, I.M.	PO -64
Korte, W.	PO -49, PO -63
Kos, C.A.	OC-06
Kotlín, R.	PO -66
Kownacki, E.	PO -49
Krajewska, U.	PO -29
Kuo, E.	OC-07
Kyrle, P.A.	PO -01

L

La Greca, M.	PO -47
Laaban, J.P.	PO -73
Lambert, Y.	PO -73

Lampugnani, M.G.	PL-01
Lange, J.	PO -49
Laperriere, N.	PO -40
Laporte, S.	PO -59
Larsen, T.B.	PO -92, PO -93
Latella, M.C.	PO -84, PO -87
Läubli, H.	OC-02
Laudisi, A.	PO -32
Lechner, D.	PO -01
Leclercq, X.	PO -73
Leda, M.S.O.	PO -23
Lee, A.Y.Y.	PL-22
Legnani, C.	PO -24
Legrand, C.	PO -35
Leone, G.	PO -104
Lester, Z.	PO -46, PO -61
Leverger, G.	PO -91
Levine, M.	PL-18, PL-23, PO -40
Levy, R.A.	PO -11, PO -23
Levy-Adam, F.	PO -04
Leyte, A.	PO -33
Li, C.	PO -76, PO -77, PO -79
Li Thiao Te, V.	PO -91
Liang, H.	PO -82
Licursi, M.	PO -22
Liebman, H.A.	OC-06, PO -16, PO -99
Lien, T.	PO -06
Lieskovsky, G.	PO -16
Lima, L.G.	PO -85
Lo Coco, L.	PO -55
Lofts, F.	PO -56
Lokare, A.	PO -46
Lorenzet, R.	PO -84, PO -87
Lorusso, G.	OC-01
Loures, M.A.L.	PO -11
Ludovici, G.	PO -05
Lundbye-Christensen, S.	PO -92, PO -93

M

Mackman, N.	PL-13
Madzhuga, A.	PO -53, PO -65
Magnapera, A.	PO -05
Makatsaria, A.	PO -20, PO -21

Makri, L.P.	PO -103
Makris, M.P.	PO -103
Makris, P.E.	PO -103
Malato, A.	PO -44, PO -55
Malkin, M.	PO -40
Manicone, R.	PO -57
Manor, O.	PO -100
Maraveyas, A.	PO -56, PO -79
Marchetti, M.	PO -12, PO -13, PO -25, PO -26, PO -33, PO -75, PO -88
Mark, L.	PO -99
Marques, I.C.	PO -23
Marr, H.	PO -19, PO -45
Marra, R.	PO -104
Martini, F.	PO -05, PO -32
Mathias, L.	PO -94
Mathiesen, E.B.	PO -98
Maurillo, L.	PO -42
McManus, A.	PO -46, PO -61
Mechinaud, F.	PO -91
Meir, A.	PO -67
Mereu, M.	PO -72
Meyer, G.	PO -59
Micheli, J.	PO -91
Mielicki, W.P.	PO -29
Mikus, G.	OC-10
Miller, C.	OC-07
Mirshahi, M.	PO -07, PO -80
Mirshahi, S.S.	PO -07, PO -80
Mismetti, P.	PO -59
Modugno, P.	PO -22
Moia, M.	PO -90
Monreal, M.	PL-08
Monteiro, R.O.	PO -11, PO -23, PO -38, PO -62, PO -85
Montesinos, P.	PL-17
Morelli, A.M.	PO -72
Morrissey, J.	PO -26
Mos, I.C.M.	PO -88
Moulin, N.	PO -59
Mowinkel, M.C.	PO -69
Muniz, R.	PO -41
Mussoni, L.	PO -09

AUTHOR INDEX

Muzi, P.PO -10
Myers, B.PO -27

N

Nadir, E.PO -04
Nadir, Y.PO -04
Naldini, A.O C-05, PO -37
Napoleone, E.PO -84, PO -87
Negaard, H.F.S.PO -69
Neri, T.PO -52
Nielsen, T.S.H.PO -92, PO -93
Niers, T.M.H.O C-08
Njølstad, I.PO -98
Noble, S.I.R.PO -39
Nokes, T.PO -46, PO -61
Noonan, D.O C-01

O

O'Connell, C.PO -99
O'Donnell, J.PO -17
Onaran, I.PO -54
Ornstein, D.L.PO -34
O'Shaughnessy, D.PO -46, PO -61
Ostenstad, B.PO -69
Otten, J.M.M.B.PO -88

P

Pabinger, I.PO -36
Palareti, G.PO -24, PO -90
Palmirotta, R.PO -05, PO -32
Paltiel, O.PO -100
Palumbo, J.S.PL-04
Panesha, S.PO -19, PO -45, PO -46
Papamichos, S.I.PO -103
Papini, S.PO -22
Parisi, A.PO -47
Parsons, N.PO -45
Pastore, G.PO -97
Patton, W.PO -18
Pautard, B.PO -91
Pedersen, L.O C-03
Perel, Y.PO -91

Perrot, J.Y.PO -07
Perry, J.PL-23, PO -40
Petropoulou, A.D.PO -74
Pfeffer, U.O C-01
Piano, S.PO -22, PO -104
Piccioli, A.PO -58
Pignieri, A.PO -09
Pinheiro, V.R.PO -11, PO -23
Pistelli, R.PO -90
Pizzini, A.PO -102
Poznansky, M.C.PO -58
Prandoni, P.PL-08, PO -58
Premazzi, M.G.PO -11
Prenzel, C.PO -83
Pressley, F.PO -46
Pugliano, M.T.PO -101
Pujade-Lauraine, E.PO -07
Pulini, S.PO -72

Q

Quaresima, M.PO -42
Quehenberger, P.PO -36
Queiroz, C.PO -41
Quinn, D.I.PO -16
Quinto, F.PO -35

R

Rafii Tabrizi, A.PO -80
Rak, J.PL-12
Rambaldi, A.PO -25
Razzari, C.PO -02
Regina, S.PO -81
Rendu, F.PO -74
Renni, M.PO -41, PO -94
Reverdiau, P.PO -81
Reynolds, J.V.PO -17
Ribeiro, F.PO -38
Ribeiro-Pinto, L.PO -38
Rickles, F.R.PL-17
Riedel, T.PO -66
Rios, F.J.PO -11
Rochanda, L.PO -16
Rogers, L.PO -40

Rollin, J.PO -81
Roman, M.P.PO -83
Ronci, B.PO -42
Rose, P.PO -19, PO -45
PO -46, PO -61
Roselli, M.PO -05, PO -32
Rosing, J.PO -75
Rossi, L.PO -05
Rossi, R.O C-07, PO -90
Rotondo, S.PO -47
Rousseau, A.PO -71
Rozalski, M.PO -29
Ruf, W.PL-02
Rumjaneck, F.PO -38
Rupoli, S.PO -43
Russo, L.PO -12, PO -13
PO -25, PO -26
Russomano, F.PO -94
Ryan, C.O C-07

S

Saccullo, G.PO -55
Salaj, P.PO -66
Salameh, M.PO -18
Samama, M.M.PO -73, PO -74
Sanderson, R.D.PL-21
Sandset, P.M.PO -30, PO -69
Sanz, M.A.PL-17
Saracco, P.PO -57, PO -97
Sarif, G.PO -67
Savonarola, A.PO -32
Sawaya, R.PO -40
Sawicki, Z.PO -28
Sayed-Ahmed, N.PO -89
Scarpi, E.PO -43
Schnider, T.PO -49
Scriven, N.PO -46, PO -61
Seeholzer, N.PO -63
Selim, T.PO -89
Sencan, S.PO -54
Sferra, R.PO -10
Sgouros, J.PO -56
Shankara, P.PO -61
Sierko, E.PO -28

Silingardi, M.	PO -102
Silini, A.	OC-05
Silveira, N.P.R.	PO -11
Simanek, R.	PO -36
Simão, T.	PO -38
Siragusa, S.	PO -44, PO -55
Skinner, D.G.	PO -16
Skretting, G.	PO -30
Slater, D.E.	PO -50
Sletten, M.	PO -06
Smorenburg, S.M.	OC-08
Soff, G.A.	PL-03
Sogayar, M.C.	PO -62
Somonova, O.	PO -53, PO -65
Søndergaard, F.	OC-03
Sørensen, H.T.	OC-03
Soria, J.	PO -07, PO -80
Specchia, M.	PO -22
Spek, C.A.	OC-08
Spronk, H.M.H.	PO -64, PO -75 PO -88
Stender, M.T.	PO -92, PO -93
Størmer, J.	PO -98
Storti, S.	PO -22, PO -104
Suttnar, J.	PO -66
Swarthout, R.	OC-07

T

Tabone, M.D.	PO -91
Tacchetti, P.	PO -03
Tagawa, S.T.	PO -16
Tagliavacca, L.	PO -02
Tambaro, R.	PO -22
Tassinari, D.	PO -43
Taubman, M.B.	OC-07
Tazzari, V.	PO -03
Teichmann, A.	PO -70
ten Cate, H.	PO -64, PO -75, PO -88
Ten Hagen, T.L.M.	OC-08
Terpstra, W.E.	PO -33
Thorlacius-Ussing, O.	PO -92, PO -93
Thürlimann, B.	PO -63
Timeus, F.	PO -57
Tiram, E.	PO -100

Tjeldhorn, L.	PO -30
Torbett, B.E.	PO -86
Tosi, P.	PO -03
Totta, P.	PO -31
Trappenburg, M.	PO -33
Tremoli, E.	PO -09
Tschan, M.P.	PO -86
Tsimafeyeu, I.	PO -53, PO -65

U

Ulutin, T.	PO -54
Uppal, N.	OC-07

V

v. Doormaal, F.F.	PO -96
v. Tempelhoff, G-F.	PO -70
v.d. Velde, E.F.	PO -96
Valdrè, L.	PO -24
Valentin, J.B.	PO -81
Van Dreden, P.	PO -71
Van Noorden, C.J.F.	OC-08
van Oerle, R.	PO -64
van Schilfgaarde, M.	PO -33
van Sluis, G.L.	PO -14
Van Tellingen, O.	OC-08
van Weert, H.	PO -96
Vanacore, R.	PO -52
Vanini, A.	PO -78
Vannier, J.P.	PO -91
Vannini, N.	OC-01
Varon, D.	OC-04
Vasan, S.	PO -99
Velten, E.	PO -70
Venditti, A.	PO -42
Venditti, D.	PO -42
Verdy, E.	PO -74, PO -83
Vergati, M.	PO -05
Verso, M.	PO -90
Vetuschi, A.	PO -10
Vianello, F.	PO -58
Vicentini, C.	PO -10
Vigna, G.B.	PO -78

Vignoli, A.	PO -12, PO -13, PO -25, PO -26
Vitale, F.V.	PO -47
Vlodavsky, I.	PL-20, PO -04
Volkova, V.	PO -20, PO -21
Vormittag, R.	PO -36
Vorobiev, A.	PO -20, PO -21

W

Wang, L.	OC-07
Wedgewood, K.	PO -56
Weiss, C.H.	OC-10
Weltermann, A.	PL-14, PO -01
Westerga, J.	PO -88
Wheatley, K.	PO -60
White, A.E.	PO -27
White, B.	PO -17
White, R.H.	PL-05, PO -95
Wilsgaard, T.	PO -98
Wojtukiewicz, M.Z.	PO -28
Wollner, M.	PO -67
Woodhams, B.	PO -26, PO -71
Wronski, S.	PO -51
Wun, T.	PO -95

Y

Yanetz, R.	PO -100
Ye, W.	PO -16
Yelizarova, A.	PO -53, PO -65
Young, A.M.	PO -51, PO -60

Z

Zaccaria, A.	PO -03
Zamagni, E.	PL-26, PO -03
Zamboni, M.M.	PO -11, PO -23
Zappacosta, B.	PO -22
Zcharia, E.	PO -04
Zelikovitz, T.	OC-04
Zhang, W.	PO -45
Zhou, H.	PO -95
Zielinski, C.	PO -36
Zimnoch, L.	PO -28
Zurlo, F.	PO -84, PO -87
Zwicker, J.I.	OC-06

GENERAL INFORMATION

Meeting Venue

The Conference takes place in Bergamo at the Congress Center Giovanni XXIII, Palazzo Rezzara, Viale Papa Giovanni XXIII, 106

Organizing Secretariat

Servizi C.E.C. Srl
Servizi Congressuali ed Eventi Culturali
Via Verdi, 18 - 24121 Bergamo - Italy
Phone +39.035.249899
Fax +39.035.237852
E-mail: info@bergamoconference.com

Registration Desk

The registration desk is located in the entrance hall of the Congress Center.

It is staffed continuously every day of the conference. The staff is at your disposal for any information. Facilities available at the registration desk include:

On-site registration

Fees for on-site registration are:

- Full (Regular): Euro 420
- Student: Euro 100
- Accompanying person: Euro 80

Message boards

Any late change in the program of the conference or personal messages will be notified here.

Telephone and fax

Available on request.

Computing, printing and xeroxing

Available on request.

Internet Point

It is located at the ground floor, close to the registration desk.

Delegate Badges

All delegates are kindly requested to wear the badge throughout the conference. Only badge holders will be admitted to the Conference, Technical Exhibition, Coffee/Tea breaks and Lunches. For the Social Events please bring with you the tickets delivered to you at registration.

Name badges are colored as follows:

Delegates	Red
Faculty	Blue
Sponsors	Green

Certificates of Attendance

They will be delivered at the registration desk starting from 1.00pm on Sunday October 28th.

Continuing Medical Education

The 4th International Conference on Thrombosis and Hemostasis Issues in Cancer has been granted for CME accreditation by:

- **European Hematology Association (EHA)**
14 CME points
for European Medical Hematologists.
- **European Society for Medical Oncology (ESMO)**
15 Category I ESMO-MORA points
for European Medical Oncologists.
- **Italian Ministry of Health**
(for Italian Participants only)
8 CME (ECM) Credits
for Medical Doctors and Biologists.
10 CME (ECM) Credits
for Laboratory Technicians.

The instructions and the forms for claiming CME Credits are included in the Congress bags.

Posters

Mounting Time:

From 8.00am Sunday October 28th.

Attendance:

During the coffee break of Sunday October 28th, 10.30am-11.00am (poster view), and during the discussion (see below).

Discussion:

There will be 8 Poster Discussion Sessions (1h 15min each), held on Sunday October 28th from 1.15pm to 2.30pm and from 2.45pm to 4.00pm, each guided by two co-chairs. See the program of the Poster discussion sessions for details (pages 13-20).

The presenting authors are required to attend during the poster view and the discussion sessions.

Dismantling:

From 4.00pm to 5.00pm Sunday October 28th. After this time the posters will be destroyed by the congress organizers.

Slide Center

Slide center is located at the ground floor close to the registration desk. All presenters should deliver their slides or pen drive/CD-ROM containing a PowerPoint presentation no later than 1 hour prior to the start of their session.

Language

The official language of the Conference is English. Translations are not provided.

Change Your Clock



Please note that during the night between Saturday 27th to Sunday 28th, the Day Light Saving Time in Italy reverts to Standard Time. Clocks fall back from 3.00am to 2.00am on Sunday 28th.

Local Transportation

There is a bus service both in the morning and late afternoon between the conference site and official congress hotels located outside the center of Bergamo.

Additional information about this service (timetable and meeting points) is available at the reception of your hotel and at the congress registration desk.

Please check also, at the registration desk, the timetable and meeting points for the transfers for the Social Events.

Meals

Coffee/tea breaks and lunches are included in the Conference fee and are served in the catering areas located at the ground and first floors.


Cloakroom

Coats and bags may be left in the designated area under the ground floor.

Exhibition

The scientific and technical exhibition is located in the foyer at the ground floor. The exhibition opening times are the same of the Conference.


LAYOUT OF THE CONGRESS CENTER



GROUND FLOOR

GROUND FLOOR

- 1: Hall and Exhibition
- 2: Registration Desk
- 3: Technical Exhibition
- 4: Room Oggioni
- 5: Slide Center
- 6: Internet Point
- 7: Cloakroom and Toilets
- 8: Catering



FIRST FLOOR

FIRST FLOOR

- 1: Room Stucchi
- 2: Catering
- 3: Catering



SECOND FLOOR

SECOND FLOOR

- 1: Room Alabastro (A & B)
- 2: Room Novelli
- 3: Room Stampa

(for registered accompanying persons)

Friday - October 26th, 2007

2.30pm-6.00pm: Visit to the Village of Crespi d'Adda (UNESCO World heritage site)

Crespi is the name of a family of cotton manufacturers from Lombardy. This family realized an "ideal workers' village" nearby their factory, along the River Adda.

The Village of Crespi d'Adda is a completely self-sufficient town, built from nothing by the owner of the factory for the workers and their families. The workers were provided with homes, gardens, vegetable gardens and all necessary local services.

In this perfect little world, the master of Crespi "reigned" from his castle and, like a caring father, satisfied all needs of his employees: "from the cradle to the grave", both inside and outside the factory, predating any official state benefits or provisions. Only those who worked in the factory could live in the Village, and the life of everybody was connected to the factory, its rhythms and its demands. The Village of Crespi d'Adda, although stylistically heterogeneous, is a remarkable example of the 19th century architecture.

- Meeting point: Congress Center at 2.30pm.
- Transfer by bus with an English speaking guide.



Village of Crespi d'Adda

7:00pm: Welcome Party at the Art Gallery "Accademia Carrara"

Followed by a guided tour of the Art Exhibition "The Future of Futurism" at the GAMEC (Gallery of Modern and Contemporary Art).



Accademia Carrara

Saturday - October 27th, 2007

9.30am - 5.30pm Historical places of Bergamo

- Monastery of Sant'Agostino, Church of San Michele at Pozzo Bianco, Cannoniera of San Michele (the town defensive system), Fountain of Lantro.
- Quick lunch break in the Upper Town.
- San Giacomo Gate, Monastery of San Benedetto and Pontida Square.

- Meeting point: Congress Center at 9.30am.



Church of San Michele
at Pozzo Bianco

8:00pm: Opera "Don Gregorio" at Donizetti Theatre



Donizetti Theatre

Sunday - October 28th, 2007

9.30am-12.30pm Guided tour of the Ancient Bergamo town

- Meeting point: Congress Center at 9.30am.



Piazza Vecchia

7:00pm: Farewell Party at the Castle of Calepio

BERGAMO

CITY OF ART




The city of Bergamo is located in Northern Italy, in the borderland between the great plain of the Po Valley and the Alps, 50 kilometers from Milan.



Bergamo was founded on a hill by an ancient settlement in the prehistorical age, which gave it the configuration that still characterizes the oldest part of the town, enclosed within walls up on the hill, while the modern town has grown on the plain. Celts, Goths, Romans, Longbards resided on the hill, but little can now be seen of them; some of the most important monuments date back to the Middle Ages.




The town reached its greatest splendour during the Renaissance when it became part of the Milan Signoria and then of the Venetian Republic. The four centuries under the Venetians were the most significant with respect to their cultural and historical impact on the city. Città Alta, the old town situated on the hill and surrounded by sixteenth-century walls, has maintained the charm of its past over the centuries, with the magic and quiet atmosphere of its belfries, towers and squares. Città Bassa, the modern town, has all the conveniences of a modern urban center. Thus Bergamo is the town where old and new come together in a harmonious expression of life.



MAP OF BERGAMO

4th International Conference on Thrombosis and Hemostasis Issues in Cancer

Bergamo, Italy ■ October 26 - 28, 2007
Congress Center Giovanni XXIII



1 Congress Center Giovanni XXIII

2 Best Western Cappello d'Oro

3 Starhotel Cristallo Palace

4 Hotel Mercure

5 Hotel Jolly

6 Hotel Excelsior San Marco

7 Una Hotel

8 Hotel Piemontese

9 Central Parking

10 Donizetti Theatre

11 Accademia Carrara
& Gamec



Servizi C.E.C. srl

Servizi Congressuali ed Eventi Culturali

Via Verdi, 18

24121 Bergamo - Italy

Phone +39.035.249899

Fax +39.035.237852

E-mail: info@bergamoconference.com

Anna Falanga

Alfonso Vignoli

Ospedali Riuniti di Bergamo

Department of Hematology/Oncology

SIMT - Hemostasis and Thrombosis Center

Largo Barozzi, 1

24128 Bergamo - Italy

E-mail: icthic.2007@yahoo.com

